TY - JOUR
T1 - Monoclonal gammopathies of clinical significance
AU - Dispenzieri, Angela
N1 - Funding Information:
A.D. has received research funding from Celgene, Millennium, Pfizer, and Alnylam; has received a travel grant from Pfizer; and has served on an advisory board for Janssen.
Publisher Copyright:
© 2020 American Society of Hematology. All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - “Monoclonal gammopathy of clinical significance” (MGCS) is the term used to describe nonmalignant monoclonal gammopathies causing important disease. MGCS is the differential diagnosis for any patient presenting with what appears to be a monoclonal gammopathy of undetermined significance but is also experiencing other unexplained symptoms. Broadly, these conditions can be separated into symptoms and signs referable to the nerves, the kidneys, and the skin. The first step in making these diagnoses is to consider them. With a particular condition in mind, the next step is to order those tests that can help confirm or dismiss a particular diagnosis. Nearly all of the renal and dermatologic conditions are diagnosed by renal and skin biopsies, respectively. The importance of a highly competent renal pathologist and dermatopathologist cannot be underestimated. Biopsy is less specific for the neuropathic conditions. Because several of the MGCSs are syndromes, recognizing other manifestations is also key. Treatment recommendations for many of these conditions are anecdotal because of their rarity, but for several of the conditions, IV immunoglobulin, rituximab, and plasma cell-directed therapy are the best options.
AB - “Monoclonal gammopathy of clinical significance” (MGCS) is the term used to describe nonmalignant monoclonal gammopathies causing important disease. MGCS is the differential diagnosis for any patient presenting with what appears to be a monoclonal gammopathy of undetermined significance but is also experiencing other unexplained symptoms. Broadly, these conditions can be separated into symptoms and signs referable to the nerves, the kidneys, and the skin. The first step in making these diagnoses is to consider them. With a particular condition in mind, the next step is to order those tests that can help confirm or dismiss a particular diagnosis. Nearly all of the renal and dermatologic conditions are diagnosed by renal and skin biopsies, respectively. The importance of a highly competent renal pathologist and dermatopathologist cannot be underestimated. Biopsy is less specific for the neuropathic conditions. Because several of the MGCSs are syndromes, recognizing other manifestations is also key. Treatment recommendations for many of these conditions are anecdotal because of their rarity, but for several of the conditions, IV immunoglobulin, rituximab, and plasma cell-directed therapy are the best options.
UR - http://www.scopus.com/inward/record.url?scp=85097310555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097310555&partnerID=8YFLogxK
U2 - 10.1182/HEMATOLOGY.2020000122
DO - 10.1182/HEMATOLOGY.2020000122
M3 - Article
C2 - 33275738
AN - SCOPUS:85097310555
SN - 1520-4391
VL - 20
SP - 380
EP - 388
JO - Hematology (United States)
JF - Hematology (United States)
IS - 1
ER -